公开(公告)号：EP1335898A1

公开(公告)日：2003-08-20

申请号：EP01970014.5

申请日：2001-09-27

申请人： Prolifix Limited

发明人： WATKINS, Clare, J. ,  ROMERO-MARTIN, Maria-Rosario ,  MOORE, Kathryn, G.,Prolifix Ltd ,  RITCHIE, James,c/o Prolifix Ltd ,  FINN, Paul, W.,c/o Prolifix Ltd ,  KALVINSH, Ivars,c/o Latvian Inst. Organic Synth. ,  LOZA, Einars,c/o Latvian Inst. Organic Synth. ,  STARCHENKOV, Igor,c/o Latvian Inst. Organic Synth ,  DIKOVSKA, Klara,c/o Latvian Inst. Organic Synth. ,  BOKALDERE, Rasma M.,c/o Latvian Inst. Orga. Synth ,  GAILITE, Vija,c/o Lativan Inst. Organic Synth. ,  VORONA, Maxim,c/o Latvian Inst. Organic Synth. ,  ANDRIANOV, Victor,c/o Latvian Inst. Organic Synth ,  LOLYA, Daina,c/o Latvian Inst. Organic Synth. ,  SEMENIKHINA, Valentina,c/o Latvian Inst. Org. Syn ,  AMOLINS, Andris,c/o Latvian Inst. Organic Synth. ,  HARRIS, C., John,c/o BioFocus plc ,  DUFFY, James, E., S.,c/o BioFocus plc

IPC分类号： C07C233/03 ,  C07C233/05 ,  C07C233/09 ,  C07C233/08 ,  C07D207/40 ,  C07D213/06 ,  C07D209/14 ,  C07D235/24 ,  C07D307/34 ,  C07D333/24 ,  C07D333/60 ,  A61P35/00

CPC分类号： C07D207/337 ,  A61K31/16 ,  A61K31/195 ,  A61K31/198 ,  A61K31/277 ,  A61K31/38 ,  A61K31/381 ,  A61K31/426 ,  C07C233/49 ,  C07C233/83 ,  C07C235/34 ,  C07C237/36 ,  C07C255/57 ,  C07C259/06 ,  C07C259/08 ,  C07C2603/18 ,  C07D207/40 ,  C07D207/404 ,  C07D209/14 ,  C07D209/16 ,  C07D209/18 ,  C07D209/22 ,  C07D213/06 ,  C07D213/55 ,  C07D213/56 ,  C07D233/04 ,  C07D233/08 ,  C07D235/14 ,  C07D235/24 ,  C07D271/06 ,  C07D307/34 ,  C07D307/54 ,  C07D317/60 ,  C07D333/24 ,  C07D333/60 ,  C07D403/12 ,  Y02A50/411

摘要： This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is an aryl group; Q is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: -NR C(=O)- and -C(=O)NR -; R is an amido substituent; and, Q is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof, for use in the treatment of parasitic infections, such as malaria.

摘要翻译： 本发明涉及某些抑制HDAC活性的活性氨基甲酸化合物，具有下式：其中：A为芳基; Q 1是具有至少2个碳原子的主链的芳基前导基团; J是选自以下的酰胺键：-NR 1 C（= O） - 和-C（= O）NR 1 - ; R 1是酰氨基取代基; 而Q 2是酸性引导基团; 和其药学上可接受的盐，溶剂合物，酰胺，酯，醚，化学保护形式及其前药，用于治疗寄生虫感染如疟疾。